Income Statement Control Bionics Limited
Stocks
CBL
AU0000114183
Advanced Medical Equipment & Technology
|
Market Closed -
Australian S.E.
23:58:58 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 0.0610 AUD | 0.00% |
|
+5.17% | - |
| 08-28 | Control Bionics Limited Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 05-13 | Control Bionics Limited Announces Board Changes, Effective May 14, 2026 | CI |
| Fiscal Period: June | 2018 (AUD) | 2019 (AUD) | 2020 (AUD) | 2021 (AUD) | 2022 (AUD) | 2023 (AUD) | 2024 (AUD) | 2025 (AUD) | 2026 (AUD) |
|---|---|---|---|---|---|---|---|---|---|
Revenues | 4.48M | 5.64M | 5.35M | 6.14M | 4.77M | ||||
Other Revenues, Total | 338K | - | - | - | - | ||||
Total Revenues | 4.81M | 5.64M | 5.35M | 6.14M | 4.77M | ||||
Cost of Goods Sold, Total | 1.98M | 1.93M | 1.45M | 2.03M | 2.41M | ||||
Gross Profit | 2.84M | 3.71M | 3.9M | 4.11M | 2.36M | ||||
Selling General & Admin Expenses, Total | 8.05M | 8.45M | 7.7M | 8.64M | 7.39M | ||||
Provision for Bad Debts | 84.61K | 237K | 414K | 233K | - | ||||
Stock-Based Compensation (IS) | - | - | - | - | 221K | ||||
R&D Expenses | 329K | 231K | 1.71M | 1.07M | 1.24M | ||||
Depreciation & Amortization - (IS) | 508K | 480K | 843K | 986K | 792K | ||||
Other Operating Expenses | - | -452K | -891K | -859K | -628K | ||||
Other Operating Expenses, Total | 8.98M | 8.95M | 9.78M | 10.07M | 9.02M | ||||
Operating Income | -6.14M | -5.24M | -5.88M | -5.96M | -6.66M | ||||
Interest Expense, Total | -42.99K | -21.33K | -56.28K | -109K | -85K | ||||
Interest And Investment Income | 1.33K | 20.14K | 12.18K | 36.67K | 6.31K | ||||
Net Interest Expenses | -41.67K | -1.19K | -44.1K | -72.3K | -78.68K | ||||
Income (Loss) On Equity Invest. | - | - | - | -58.08K | -47.81K | ||||
Currency Exchange Gains (Loss) | 24.28K | -2.76K | 4.17K | -10.77K | 3.8K | ||||
Other Non Operating Income (Expenses) | -33.75K | - | - | - | -279K | ||||
EBT, Excl. Unusual Items | -6.19M | -5.24M | -5.92M | -6.1M | -7.06M | ||||
Gain (Loss) On Sale Of Investments | - | - | - | - | -201K | ||||
Asset Writedown | - | - | - | -10.08K | - | ||||
Other Unusual Items | 88.93K | -392K | 7.92K | - | - | ||||
EBT, Incl. Unusual Items | -6.1M | -5.63M | -5.91M | -6.11M | -7.27M | ||||
Earnings From Continuing Operations | -6.1M | -5.63M | -5.91M | -6.11M | -7.27M | ||||
Net Income to Company | -6.1M | -5.63M | -5.91M | -6.11M | -7.27M | ||||
Net Income - (IS) | -6.1M | -5.63M | -5.91M | -6.11M | -7.27M | ||||
Net Income to Common Incl Extra Items | -6.1M | -5.63M | -5.91M | -6.11M | -7.27M | ||||
Net Income to Common Excl. Extra Items | -6.1M | -5.63M | -5.91M | -6.11M | -7.27M | ||||
Per Share Items | |||||||||
Net EPS - Basic | -0.07 | -0.06 | -0.04 | -0.02 | -0.02 | ||||
Basic EPS - Continuing Operations | -0.07 | -0.06 | -0.04 | -0.02 | -0.02 | ||||
Basic Weighted Average Shares Outstanding | 85.28M | 90.23M | 159M | 264M | 371M | ||||
Net EPS - Diluted | -0.07 | -0.06 | -0.04 | -0.02 | -0.02 | ||||
Diluted EPS - Continuing Operations | -0.07 | -0.06 | -0.04 | -0.02 | -0.02 | ||||
Diluted Weighted Average Shares Outstanding | 85.28M | 90.23M | 159M | 264M | 371M | ||||
Normalized Basic EPS | -0.05 | -0.04 | -0.02 | -0.01 | -0.01 | ||||
Normalized Diluted EPS | -0.05 | -0.04 | -0.02 | -0.01 | -0.01 | ||||
Supplemental Items | |||||||||
EBITDA | -5.72M | -4.87M | -5.16M | -5.14M | -6M | ||||
EBITA | -6.13M | -5.23M | -5.75M | -5.65M | -6.33M | ||||
EBIT | -6.14M | -5.24M | -5.88M | -5.96M | -6.66M | ||||
EBITDAR | - | - | - | - | - | ||||
Total Revenues (As Reported) | 4.9M | 6.11M | 6.36M | - | - | ||||
Normalized Net Income | -3.87M | -3.27M | -3.7M | -3.81M | -4.42M | ||||
Interest on Long-Term Debt | 34.11K | 9.02K | - | 60.82K | 34.94K | ||||
Supplemental Operating Expense Items | |||||||||
Marketing Expenses | 712K | 617K | 461K | 414K | 388K | ||||
Selling and Marketing Expenses | 712K | 617K | 461K | 414K | 388K | ||||
General and Administrative Expenses | 2.01M | 2.11M | 1.2M | 1.54M | 1.05M | ||||
Research And Development Expense From Footnotes | 329K | 231K | 1.71M | 1.07M | 1.24M | ||||
Net Rental Expense, Total | - | - | - | - | - | ||||
Imputed Operating Lease Interest Expense | - | - | - | - | - | ||||
Imputed Operating Lease Depreciation | - | - | - | - | - | ||||
Stock-Based Comp., SG&A Exp. (Total) | 51.7K | 27.21K | 137K | 124K | - | ||||
Stock-Based Comp., Other (Total) | - | 12.04K | - | - | 221K | ||||
Total Stock-Based Compensation | 51.7K | 39.24K | 137K | 124K | 221K |
- Stock Market
- Stocks
- CBL Stock
- Financials Control Bionics Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















